Immunotherapy plus chemo before surgery for lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests combining two immunotherapy drugs (iparomlimab and tuvonralimab) with 2 or 4 cycles of chemotherapy before surgery for patients with stage II to IIIB non-small cell lung cancer that can be removed. It aims to see if this approach helps shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have non-small cell lung cancer that hasn't been treated yet, at stage II or IIIB (with N2 lymph node involvement only).
- A tumor board including a chest surgeon has agreed your cancer can be surgically removed.
- You are able to provide a tissue sample for testing, such as for PD-L1 levels or gene mutations.
- You have at least one tumor that can be measured on scans.
- You are in good enough health to be up and about (ECOG performance status 0 or 1).
- You do not have certain gene mutations (EGFR or ALK) or other cancers in the last 5 years, and you haven't had certain immunotherapy or strong steroid treatments recently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two immunotherapy drugs (iparomlimab and tuvonralimab) combined with chemotherapy given before surgery to remove stage III lung cancer. The goal is to shrink the tumor and improve survival chances by boosting your immune system to fight the cancer.
This trial tests combining immunotherapy with chemotherapy for people with stage III non-small cell lung cancer that cannot be removed by surgery. It aims to see if this combination can shrink the tumor and improve outcomes.
This trial tests if two immunotherapy drugs (iparomlimab and tuvonralimab) combined with chemotherapy can shrink stage III lung cancer that cannot be surgically removed, making it possible to operate. It is for people who have not had prior treatment for their lung cancer and are healthy enough for surgery.
This trial tests a new combination of an immunotherapy drug (IBI363) plus chemotherapy before surgery in people with Stage III lung cancer that can't be removed at first. The goal is to shrink the tumor so it can be surgically removed.
This trial tests whether giving an immune-boosting drug (Tα1) along with chemotherapy and immunotherapy before surgery helps people with stage II-IIIB non-small cell lung cancer that can be removed. It aims to see if this combination makes the cancer shrink more and improves outcomes.
This trial tests a combination of an immunotherapy drug (adebrelimab) plus chemotherapy and another drug (recaticimab) before and after surgery for people with stage II or III lung cancer that can be removed. The goal is to see if this approach helps shrink tumors and improves outcomes.
Hear when a new Carcinoma, Non-Small-Cell Lung trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.